852 related articles for article (PubMed ID: 26470624)
21. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
Shuja F; Chan CS; Rosen T
Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
[TBL] [Abstract][Full Text] [Related]
22. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
23. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
24. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.
Sachdeva M; Kim P; Mufti A; Maliyar K; Sibbald C; Alavi A
J Cutan Med Surg; 2022; 26(2):176-180. PubMed ID: 34587768
[TBL] [Abstract][Full Text] [Related]
25. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
27. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
[TBL] [Abstract][Full Text] [Related]
28. Hidradenitis suppurativa in the pediatric population.
Liy-Wong C; Pope E; Lara-Corrales I
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
[TBL] [Abstract][Full Text] [Related]
29. Biologic Treatment for Hidradenitis Suppurativa.
Flood KS; Porter ML; Kimball AB
Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
[TBL] [Abstract][Full Text] [Related]
30. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
Tchernev G
Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
[TBL] [Abstract][Full Text] [Related]
31. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
32. Long-term therapy with anakinra in hidradenitis suppurativa in three patients.
André R; Marescassier H; Gabay C; Pittet B; Laffitte E
Int J Dermatol; 2019 Nov; 58(11):e208-e209. PubMed ID: 31353451
[No Abstract] [Full Text] [Related]
33. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
Haslund P; Lee RA; Jemec GB
Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
[TBL] [Abstract][Full Text] [Related]
34. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
[TBL] [Abstract][Full Text] [Related]
37. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
38. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
39. Hidradenitis suppurativa managed with adalimumab.
Yamauchi PS; Mau N
J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
[TBL] [Abstract][Full Text] [Related]
40. Infliximab for the treatment of hidradenitis suppurativa.
Fernández-Vozmediano JM; Armario-Hita JC
Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]